Inflammation as a Link between Obesity and Metabolic Syndrome by Emanuela, Faloia et al.
Hindawi Publishing Corporation
Journal of Nutrition and Metabolism
Volume 2012, Article ID 476380, 7 pages
doi:10.1155/2012/476380
Review Article
Inﬂammation as a LinkbetweenObesityand Metabolic Syndrome
FaloiaEmanuela,Michetti Grazia,DeRobertisMarco, LuconiMariaPaola,
FurlaniGiorgio,andBoscaroMarco
Division of Endocrinology, Polytechnic University of Marche, via Conca 71, 60126 Ancona, Italy
Correspondence should be addressed to Faloia Emanuela, e.faloia@univpm.it
Received 1 July 2011; Revised 19 October 2011; Accepted 3 November 2011
Academic Editor: H. Vannucchi
Copyright © 2012 Faloia Emanuela et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The metabolic syndrome is a complex of clinical features leading to an increased risk for cardiovascular disease and type 2
diabetes mellitus in both sexes. Visceral obesity and insulin resistance are considered the main features determining the negative
cardiovascular proﬁle in metabolic syndrome. The aim of this paper is to highlight the central role of obesity in the development of
a chronic low-grade inﬂammatory state that leads to insulin resistance, endothelial and microvascular dysfunctions. It is thought
that the starting signal of this inﬂammation is overfeeding and the pathway origins in all the metabolic cells; the subsequent
increaseincytokineproductionrecruitsimmunecellsintheextracellularenvironmentinducinganoverallsystemicinﬂammation.
This paper focuses on the molecular and cellular inﬂammatory mechanisms studied until now.
1.Introduction
Metabolic syndrome represents one of the major public
health challenges worldwide. Diﬀerent deﬁnitions are avail-
able describing overlapping but not identical population
[1]. The ﬁrst description goes back to 1988 when Reaven
described Syndrome X as the association of insulin resis-
tance, elevated glucose, hypertension, low HDL cholesterol,
and augmented VLDL triglycerides [2]. However he did
not include obesity, now identiﬁed as one of the essential
criterion, especially visceral obesity [1].
Overweight and obesity progress to metabolic syndrome
through pathophysiological mechanisms at the moment
largely unclear. It has been hypothesized that the state
of chronic low-grade inﬂammation associated with excess
adipose tissue may explain the development of the obesity-
related pathologies, such as type 2 diabetes mellitus and car-
diovascular disease. This inﬂammatory response is diﬀerent
from the classical responce deﬁned by the cardinal signs of
redness, swelling, heat, and pain [3, 4]. Furthermore, it plays
an important role in the development of insulin resistance
that triggers the associated comorbidities of metabolic syn-
drome, such as atherosclerosis, dyslipidemia, hypertension,
prothrombotic state, and hyperglycemia [5–8].
2. Metabolic Syndrome
2.1. Prevalence and Deﬁnition. The metabolic syndrome is
identiﬁed as a condition of increased risk for cardiovascular
disease (CVD) and type 2 diabetes mellitus (T2DM) in both
sexes. Subjects with metabolic syndrome have three times
risk of suﬀering a heart attack or stroke, twice of dying from
such an event, and ﬁvefold greater risk of developing type
2 diabetes mellitus when compared to people without the
metabolic syndrome [9].
It was ﬁrst described in 1920 when Kylin, a Swedish
physician, demonastrated the association of high blood pres-
sure (hypertension), high blood glucose (hyperglycaemia),
and gout [10]. Later in 1947, Vague described that the
visceral obesity was commonly associated with the metabolic
abnormalities found in CVD and T2DM [11].
The prevalence of metabolic syndrome varies depending
on the deﬁnition applied, the ethnicity, and the age of
the study population. The two currently used deﬁnitions
are that of the American Heart Association/National Heart,
Lung, and Blood Institute (AHA/NHLBI) and the other
one of the International Diabetes Federation (IDF). They
describe overlapping but not identical populations. The
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of three of ﬁve possible components, whereas the second
one identiﬁes in the waist circumference, and therefore in
the abdominal obesity, the mandatory diagnostic criterion
(Table 1)[ 12, 13].
Both AHA/NHLBI and IDF recognize the need of a
variable deﬁnition of elevated waist circumference among
diﬀerent populations. The IDF suggests for Europids a
threshold for increased waist circumference of at least 94cm
in men and 80cm in women; whereas the AHA/NHLBI
deﬁnes for the US population the cutoﬀ of at least 102cm for
menand88cmforwomen(Table 1)[12,13].Twoimportant
studies show the rationale for using diﬀerent cut-oﬀ points
of waist circumference in people of Asian extraction [14, 15].
East Asian and South Asian populations may have signiﬁcant
diﬀerences in lipid indices, fat mass as a proportion of BMI
and cardiovascular morbidity. More studies are necessary to
clarify these diﬀerences before consensus on separate cutoﬀs
for waist circumference will be established for these ethnic
groups [16].
3. MetabolicSyndrome as a Risk Condition
It is evident that a condition characterized by multiple risk
factors will carry a greater risk for adverse clinical outcomes.
The so-called classic risk factors of cardiovascular disease
(CVD) and coronary heart disease (CHD) include many
of the components of the metabolic syndrome. The most
widely applied prediction equation is the Framingham risk
score, less well validated for persons with T2DM rather than
without T2DM [17]. More recently, Oxford investigators
have developed a risk engine based on the large UK Prospec-
tive Diabetes Study (UKPDS) database with validated CVD
risk estimate for people with T2DM [18–20]. Both methods
take into consideration clinical parameters, as well as age,
smoking,bloodpressure,andserumlipidlevels.TheUKPDS
risk engine also includes duration of diabetes and plasma
glucose levels.
4.Obesity
4.1. Prevalence and Deﬁnition. Obesity is a metabolic disease
of pandemic proportion. The World Health Organization
estimates that 300 million of adults worldwide are obese and
more than 1 billion are overweight [21].
Obesity is commonly classiﬁed into subgroups depend-
ing on suspected etiology: monogenic obesity, syndromic
obesity, and polygenic or common obesity [22].
The monogenic obesity is an autosomal form character-
izedbyanextremelysevereobesityintheabsenceofdevelop-
mental delays; there are about 20 single gene disruptions that
result in an autosomal form of obesity [23]. Interestingly, all
these mutations position the leptin/melanocortin pathway in
the central nervous system (CNS) as critical in the regulation
ofwhole-bodyenergyhomeostasis,andobesityinthesecases
appears to be the result of increased appetite and diminished
satiety [24].
Syndromic obesity arises from discrete genetic defects
or chromosomal abnormalities at several genes, and it can
be autosomal or X-linked. They are clinically obese subjects
additionally distinguished by mental retardation, dysmor-
phic features and organ-speciﬁc developmental abnormali-
ties; one of the most well-known forms of syndromic obesity
is Prader-Willi syndrome [22].
The most common form of obesity, which aﬀects the
general population, is the polygenic form resulting from
a long-term positive energy balance; the energy excess is
stored in adipose tissue and, if this process is prolonged,
obesity develops. The balance between energy intake and
expenditure is inﬂuenced by a complex interplay of genetic,
environmental, and social factors. In common obesity, some
yet unclear signals lead to insulin resistance and to health
risks, such as increased risk of CVD [25].
A positive energy balance or obesity can also be sec-
ondary to systemic disorders: hypothyroidism diminishes
energy need, insulinoma causes obesity by promoting energy
intake via recurrent hypoglycemia, and Cushing disease is
associated with obesity of the classical centripetal type.
Other etiological factors of obesity include the binge eat-
ing disorder, a high glycemic diet, a sedentary lifestyle,
and use of certain medications like psychotropic drugs
[26].
Obesity is a potent risk factor for metabolic and car-
diovascular disease at the population level. At the indi-
vidual patient level, however, correlations between body
mass index and cardiovascular disease are not always
straightforward due, in part, to diﬀerences among adipose
tissue depots with respect to the overall rate of adipocyte
dysfunction, tissue vascularization, and local degree of
inﬂammation. Adipose tissue develops in several distinct
anatomical depots within the body, and the diﬀerential
expansion of these depots is of great importance. Expan-
sion of visceral or abdominal white adipose tissue (WAT)
has been most strongly correlated to insulin resistance
and cardiovascular disease in humans and animals. Sev-
eral studies have documented that peripheral adiposity
(especially leg fat) may protect against cardiovascular risk
[27, 28].
5. Obesity andInﬂammation
One challenge aspect of metabolic syndrome is under-
standing the cellular mechanisms that link the metabolic
abnormalities with the pathophysiological eﬀects that later
generate clinical disease.
The link between obesity and inﬂammation has been
derived from the ﬁnding that proinﬂammatory cytokines are
overexpressed in obesity [29].
Adipose tissue is an heterogeneous mix of adipocytes,
stromal preadipocytes, immune cells, and endothelium,
and it can respond rapidly and dynamically to alterations
in nutrient excess through adipocyte hypertrophy and
hyperplasia [30]. With obesity and progressive adipocyte
enlargement, the blood supply to adipocytes may be reduced
with consequent hypoxia [31]. Hypoxia has been proposed
to be an inciting etiology of necrosis and macrophage
inﬁltration into adipose tissue that leads to a overproduction
of proinﬂammatory factors like inﬂammatory chemokines.
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that propagates an overall systemic inﬂammation associ-
ated with the development of obesity-related comorbidities
[32]. This paper will focus on three adipokine produced
by macrophages: tumor necrosis factor-alpha (TNF-α),
interleukin-6 (IL-6), and adiponectin [33].
TNF-α. It is a proinﬂammatory cytokine that exerts numer-
ous eﬀects in adipose tissue including lipid metabolism and
insulin signaling whose circulating levels are increased with
obesityanddecreasedwithweightloss.AnincreaseinTNF-α
promotes the secretion of other proinﬂammatory cytokines
IL-6 and TNF-α, and reduces anti-inﬂammatory cytokines
like adiponectin [34]. Evidence suggests that TNF-α induces
adipocytes apoptosis [35] and promotes insulin resistance by
the inhibition of the insulin receptor substrate 1 signaling
pathway [36].
IL-6. The primary source of circulating IL-6 is macrophages
that have inﬁltrated WAT; IL-6 has an important role in the
regulationofwhole-bodyenergyhomeostasisandinﬂamma-
tion. Both in vitro and in vivo studies have conﬁrmed that
IL-6 is capable of suppressing lipoprotein lipase activity. IL-6
receptor is also expressed in several regions of the brain, such
asthehypothalamus,inwhichitcontrolsappetiteandenergy
intake [37].
Adiponectin. Weight loss has been shown to increase
adiponectin levels; in animal models of obesity and insulin
resistance, its levels are reduced. Adiponectin regulates
lipid and glucose metabolism, increases insulin sensibil-
ity, regulates food intake and body weight, and protects
againstchronicinﬂammation[38].Humanstudiesshowthat
hypoadiponectinemia is associated with insulin resistance,
hyperinsulinemia, and the possibility of developing type 2
diabetes, independent of fat mass [39].
Furthermore, more recent studies have been focused
on the intracellular pathways of inﬂammation. In obesity,
it is thought that the starting signal of inﬂammation is
overfeeding and the pathway origins in all the metabolic
cells, for example, in the adipocyte, hepatocyte, or myocyte.
Studies in mice and humans evidence that consumption of
nutrients may acutely evoke inﬂammatory responses [40,
41]. Metabolic cells, such as adipocytes, respond to this
insult beginning the inﬂammatory response. In obese men
and women, if compared with lean controls, adipose tissue
and liver display an increased activation of three kinases
able to induce the expression of inﬂammatory cytokines: the
c-jun N-terminal kinase (JNK), the inhibitor of k kinase
(IKK), and the protein kinase R (PKR) [42, 43]. In the
same metabolic tissues, the inﬂammasome and the Toll-
like receptors (TLRs) of the innate immune system are also
activated [44–46]. Nutrients or inﬂammatory signals may
activate the TLRs pathways and downstream JNK, IKK,
and PKR. These kinases regulate downstream transcrip-
tional programs through the transcription factors activator
protein-1 (AP-1), NF-κB, and interferon regulatory factor
(IRF),inducingupregulationofinﬂammatorymediatorgene
expression. The increase in cytokines exacerbates receptor
activation by establishing a positive feedback loop of inﬂam-
mation and the inhibitory signaling of metabolic pathways
[8].
The hypothesis is that nutrients are not self and therefore
elicit an immune response when metabolized, or they are
naturally associated with inﬂammatory molecules released
into the circulation [47, 48]. In lean healthy animals, a low
pulsatile inﬂammatory response occurs during the feeding
and resolves after the nutrients are metabolized [40, 41]. In
obesity or in overfeeding, responses become more intense
a n dr e s o l u t i o nl e s se ﬃcient. These signals accumulate over
time and may reach a level where the professional immune
cells are recruited and activated leading to an unresolved
inﬂammatory response within the tissue [43, 45]. The
quality of diet may produce diﬀerent responses: a diet rich
in fruit and ﬁbre is reported to not induce signiﬁcant
inﬂammation compared to an equicaloric high-fat diet
[49].
6. InsulinResistance and
Endothelial/MicrovascularDysfunction
Inﬂammation in obesity results in the inhibition of
the insulin receptor signaling cascade: the three kinases
described above, JNK-IKK-PKR, can target insulin receptor
substrate 1 (IRS-1) for serine phosphorilation and degrada-
tion [6–8].
Insulin has important eﬀects on the endothelium,
increasing nitric oxide (NO) availability and stimulating
vasodilatation [50]. In contrast, insulin resistance is associ-
ated with endothelial dysfunction. [51, 52].
Endothelialandmicrovasculardysfunctionarepresentin
obese subjects and represent important factors in metabolic
disturbances, since they could inﬂuence both vascular resis-
tance and insulin-mediated glucose disposal, contributing to
hypertension and insulin resistance in obesity [52, 53].
Endothelial dysfunction is an early process in obesity:
it is present even in the absence of hypertension or hyper-
glycemia, and it is associated with visceral obesity suggesting
that obesity is an independent risk factor. It is characterized
byimpairedendothelium-dependentvasodilatation,reduced
arterial compliance, and accelerated process of atherosclero-
sis [54].
It has been hypothesised an inﬂammatory aetiology for
both obesity and atherosclerosis [55–57]. Immune cells play
an important role in all stages of the atherosclerotic process
[58]; in addiction, a reduction in NO, a key regulator of
endothelial homeostasis, and an increase in reactive oxygen
species result in endothelial dysfunction and a proathero-
genic vascular bed [59].
Therefore, Gavin and collegues demonstrated a
microvascular dysfunction in obese subjects resulting
in a reduction on capillary density in skeletal muscle and
skin when compared to lean individuals. This produces a
blunted response to vasodilatation induced by oral glucose
loading probably due to impaired capillary recruitment in
response to an increased plasma insulin level. There is also a
reduction in transcapillary delivery of insulin to muscle in
obese subjects [60].4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: The most widely used deﬁnitions for metabolic syndrome.
AHA/NHLBI [12]:
At least three of the following ﬁve features
IDF [13]:
Elevated waist circumference plus any two of the other features
Waist circumference Waist circumference
(i) Non-Asian origin:
≥102cm in men or ≥88cm in women
(i) Europids, Sub-Saharan Africans, Middle Eastern:
≥94cm in men or ≥80cm in women
(ii) Asian origin (both East and South Asians):
≥90cm in men or ≥80cm in women
(ii) both East Asians and South Asians;
South and Central Americans:
≥90cm in men or ≥80cm in women
(iii) Japanese:
≥85cm in men or ≥90cm in women
Triglycerides (fasting)
≥150mg/dL or on drug therapy for high triglycerides
Triglycerides (fasting)
≥150mg/dL or on drug therapy for high triglycerides
HDL cholesterol
<40mg/dL in men or <50mg/dL in women or on
drug therapy for low HDL-C
HDL cholesterol
<40mg/dL in men or <50mg/dL in women or on
drug therapy for low HDL-C
Blood pressure
≥130mmHg systolic or ≥85mmHg diastolic or on
drug therapy for hypertension
Blood pressure
≥130mmHg systolic or ≥85mmHg diastolic or on
drug therapy for hypertension
Glucose (fasting)
≥1 0 0m g / d Lo ro ro nd r u gt h e r a p yf o re l e v a t e dg l u c o s e
Glucose (fasting)
≥1 0 0m g / d Lo ro ro nd r u gt h e r a p yf o re l e v a t e dg l u c o s e
AHA/NHLBI:AmericanHeartAssociation/NationalHeart,Lung,andBloodInstitute;IDF:InternationalDiabetesFederation;HDL:high-densitylipoprotein.
7. The Effect of Different Therapeutic
Approaches on Inﬂammatory Markers
Considering the obesity-induced inﬂammatory state, studies
from the literature have evaluated therapeutic interventions
by interfering with inﬂammatory mediators.
In patients with type 2 diabetes mellitus, the pancreatic
IL1-receptor antagonist (IL-1Ra) expression is reduced and
high glucose concentrations induce IL-1 production in β-
cells leading to impaired insulin secretion, decreased cell
proliferation, and apoptosis. Larsen et al., using anakinra,
a recombinant human IL-1Ra, in 70 patients with type 2
diabetes mellitus, observed after 13 weeks an improved β-
cell secretory function (reduced glycated haemoglobin level,
enhanced C-peptide secretion, reduced ratio of proinsulin
to insulin) and a reduction of IL-6 and C-reactive protein,
markers of systemic inﬂammation [61]. The same authors in
a39-weekfollow-upstudyinvestigatedthedurabilityofthese
responses: the reduced proinsulin/insulin ratio and CRP and
IL-6 serum levels were maintained. The improvement in
β-cell function could be a consequence of inhibited IL-1
signaling and not only of improved glycaemia per se [62].
In obese humans are observed increased circulating levels
of TNF-α; this event has been proposed to be causatively
involved in the evolution of insulin resistance, type 2
diabetes, and its complications.
Animal studies showing that interference with TNF-
α signaling protects against developing the metabolic syn-
dromeinobesityandstudiesinpatientswithchronicinﬂam-
matory conditions, such as rheumatoid arthritis and psori-
asis, clearly show that quenching TNF-α activity improves
insulin sensitivity [63, 64].
Alternatively, some studies were conducted to demon-
stratetheeﬀectofTNF-αneutralizationoninsulinsensitivity
in patients with type 2 diabetes: most of them indicated
no appreciable eﬀect of TNF-α neutralization on insulin
sensitivity [65–67].The basis for this controversy is unclear
but may relate to patient populations studied or length
of clinical trials; all these studies potentially did not allow
suﬃcient time for normalization of the metabolic derange-
ments. In fact more recently, a long-term study conducted
in obese subjects with glucose alterations and subclinical
inﬂammation treated with etanercept, TNF-α antagonist,
found an improved fasting glucose, increased ratio of high
molecular weight (HMW) adiponectin to total adiponectin,
and decreased soluble intracellular adhesion molecule-1
(sICAM) [68].
However, this evidence brings to question whether in
TNF-α is a causative link between adiposity and insulin
resistance [69].
The thiazolidinediones (TZDs), a class of potent agonists
of peroxisome proliferator activated receptor-γ (PPARγ),
increasing the activation of this transcription factor in
adipose tissue, restores lipogenic function and decrease
inﬂammation [70]. TZDs also block the ability of TNF-α to
alter the most proximal steps of insulin signaling through
the serine phosphorylation of insulin receptor and increase
adiponectin expression [71]. One in vitro study demon-
strated that adiponectin exerts potent immunosuppressive
properties inducing the production of anti-inﬂammatory
mediators IL-10 and IL-1 receptor antagonist (IL-1Ra) in a
varietyofmyeloidcelltypes.IL-10caninhibittheproduction
of many other proinﬂammatory cytokines including IL-1,
IL-2, INFγ,a n dT N F - α and impairs the phagocytic and all-
stimulatory capacity of macrophages [72].
In addition, adiponectin through the upregulation of IL-
10 increases the tissue inhibitor metalloproteinase-1 (TIMP-
1) levels in human macrophages preventing the extracellular
degradation [73].J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Metabolic syndrome
Hypertension
• Adipocyte hypertrophy/
hyperplasia
• Hypoxia/necrosis
• Macrophage inﬁltration
• Activation of JNK, IKK,
PKR
• Activation of Toll-like 
receptors
Alterations in lipid and 
glucose metabolism
Proinﬂammatory state
Atherosclerosis
Insulin resistance
Proinﬂammatory state
↑TNF-α, ↑IL-6, ↓adiponectin
Endothelial/microvascular dysfunction
↓NO, ↑ROS
Figure 1: Mechanisms linking abdominal obesity and metabolic syndrome. TNF-α: tumour necrosis factor alpha; IL-6: interleukin 6; NO:
nitric oxide; ROS: reactive oxygen species; JNK: c-jun N-terminal kinase; IKK: Inhibitor of k kinase; PKR: protein kinase R.
8. Conclusions
The association between visceral obesity and metabolic
syndrome is well known, but the pathophysiological mecha-
nisms that explain this link are not completely understood.
Metabolic syndrome is a complex of clinical features, the
most important of which is an increased visceral fat depot.
Obesity results in a proinﬂammatory state starting in the
metabolic cells (adipocyte, hepatocyte, or myocyte) and
also recruiting immune cells with the consequent release of
inﬂammatory cytokines (TNF-α, IL-6, adiponectin, etc.). It
has been hypothesized that the obesity-induced inﬂamma-
tory process may lead to complications such as hyperten-
sion, atherosclerosis, dyslipidaemia, insulin resistance, and
diabetes mellitus which characterize metabolic syndrome
(Figure 1),butotherstudiesarenecessarytofocusontherole
of adipose tissue in the pathogenesis of diabetes mellitus and
cardiovascular disease.
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